Literature DB >> 16464956

HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites.

Chad A Dickey1, Judith Dunmore, Bingwei Lu, Ji-Wu Wang, Wing C Lee, Adeela Kamal, Francis Burrows, Christopher Eckman, Michael Hutton, Leonard Petrucelli.   

Abstract

Neurofibrillary tangles (NFTs) are a characteristic neuropathological feature of Alzheimer's disease (AD), and molecular chaperones appear to be involved in the removal of disease-associated hyperphosphorylated tau, a primary component of NFTs. Here, novel HSP90 inhibitors were used to examine the impact of chaperone elevation on clearance of different tau species in transfected cells using a unique quantitative assay. The HSP90 inhibitors reduced levels of tau phosphorylated at proline-directed Ser/Thr sites (pS202/T205, pS396/S404) and conformationally altered (MC-1) tau species, an epitope that is immeasurable by standard Western blot techniques. The selective clearance of these phospho-tau species and MC-1 tau was mediated via the proteasome, while lysosomal-mediated tau degradation seems to lack specificity for certain tau species, suggesting a more general role in total tau removal. Interestingly, tau phosphorylated at S262/S356 within the tau microtubule binding domain was minimally affected by chaperone induction. Overall, our data show that chaperone induction results in the selective clearance of specific phospho-tau and conformationally altered tau species mediated by the proteasome; however, the apparent stability of pS262/S356 tau may also explain why MARK is able to regulate normal tau function yet still be linked to the initiation of pathogenic tau hyperphosphorylation in AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16464956     DOI: 10.1096/fj.05-5343fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  77 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases.

Authors:  Daniel W Neef; Alex M Jaeger; Dennis J Thiele
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

4.  NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy.

Authors:  Yousuf O Ali; Kai Ruan; R Grace Zhai
Journal:  Hum Mol Genet       Date:  2011-09-30       Impact factor: 6.150

5.  [Molecular principles of tau-induced toxicity: new experimental therapy strategies for treatment of Alzheimer's disease].

Authors:  A Schneider; P Falkai; A Papassotiropoulos
Journal:  Nervenarzt       Date:  2010-11       Impact factor: 1.214

6.  Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases.

Authors:  Umesh K Jinwal; John Koren; John C O'Leary; Jeffrey R Jones; Jose F Abisambra; Chad A Dickey
Journal:  Mol Cell Pharmacol       Date:  2010-01-01

7.  Accelerated neurodegeneration through chaperone-mediated oligomerization of tau.

Authors:  Laura J Blair; Bryce A Nordhues; Shannon E Hill; K Matthew Scaglione; John C O'Leary; Sarah N Fontaine; Leonid Breydo; Bo Zhang; Pengfei Li; Li Wang; Carl Cotman; Henry L Paulson; Martin Muschol; Vladimir N Uversky; Torsten Klengel; Elisabeth B Binder; Rakez Kayed; Todd E Golde; Nicole Berchtold; Chad A Dickey
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

8.  Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Authors:  Chad Dickey; Clara Kraft; Umesh Jinwal; John Koren; Amelia Johnson; Laura Anderson; Lori Lebson; Daniel Lee; Dennis Dickson; Rohan de Silva; Lester I Binder; David Morgan; Jada Lewis
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

10.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.